Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

We describe a case of a 46-year-old woman diagnosed with localized PTC 20 years ago, having already undergone several treatments with iodine-131 and then treatment with lenvatinib for metastatic disease, to which she developed intolerance. In 2020, in addition to pleural, thoracic, and abdominal lym...

Full description

Bibliographic Details
Main Authors: Joana S. Reis, Inês Costa, Mariana Costa, Ana Carmo Valente, Marta Baptista Freitas, Catarina Lopes Almeida, Marina Gonçalves, Carina Teixeira, Maria Ribeiro, Cláudia Caeiro, Catarina Fernandes, Miguel Barbosa
Format: Article
Language:English
Published: Karger Publishers 2022-11-01
Series:Case Reports in Oncology
Subjects:
precision oncology
braf mutation
metastatic thyroid cancer
braf inhibitors
lenvatinib intolerance
Online Access:https://www.karger.com/Article/FullText/526533

Internet

https://www.karger.com/Article/FullText/526533

Similar Items